| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H16ClN5O3 |
| Molecular Weight | 409.826 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)C1=NC=CC(COC2=NN=C(NC3=CC=C(Cl)C=C3)C4=C2OC=C4)=C1
InChI
InChIKey=QFCXANHHBCGMAS-UHFFFAOYSA-N
InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)
| Molecular Formula | C20H16ClN5O3 |
| Molecular Weight | 409.826 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Telatinib (Bay-579352) developed by Bayer is an orally available and highly potent inhibitor of tyrosine kinases VEGFR2,VEGFR3, PDGFR and c-Kit. Telatinib is a potent inhibitor of angiogenesis. Telatinib caused a significant decrease in endothelium-dependent and endothelium-independent vasodilation. Telatinib demonstrates anti-tumor activity in various cancer models. Telatinib is ready for phase III clinical trials for the treatment of gastric cancer. In 2010, it has been granted orphan drug status by the FDA. Most frequent adverse events were pain, nausea, voice changes and fatigue.
Originator
Approval Year
Sourcing
| Vendor/Aggregator | ID | URL |
|---|---|---|
Patents
Sample Use Guides
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB32825 | PRIMARY | |||
|
C80869 | PRIMARY | |||
|
100000126084 | PRIMARY | |||
|
9808844 | PRIMARY | |||
|
8795 | PRIMARY | |||
|
18P7197Q7J | PRIMARY | |||
|
DB15393 | PRIMARY | |||
|
CHEMBL2079588 | PRIMARY | |||
|
DTXSID70954809 | PRIMARY | |||
|
332012-40-5 | PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
